Martin Lenter

3.9k total citations
44 papers, 3.1k citations indexed

About

Martin Lenter is a scholar working on Molecular Biology, Immunology and Allergy and Cancer Research. According to data from OpenAlex, Martin Lenter has authored 44 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 9 papers in Immunology and Allergy and 9 papers in Cancer Research. Recurrent topics in Martin Lenter's work include Cell Adhesion Molecules Research (9 papers), Protease and Inhibitor Mechanisms (8 papers) and Glycosylation and Glycoproteins Research (5 papers). Martin Lenter is often cited by papers focused on Cell Adhesion Molecules Research (9 papers), Protease and Inhibitor Mechanisms (8 papers) and Glycosylation and Glycoproteins Research (5 papers). Martin Lenter collaborates with scholars based in Germany, Austria and United States. Martin Lenter's co-authors include Dietmar Vestweber, Wolfgang J. Rettig, Pilar Garin‐Chesa, John E. Park, Lloyd J. Old, Sandra Isenmann, Agneta Levinovitz, Masayuki Ozawa, Rolf Kemler and Christoph Eckerskorn and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Martin Lenter

44 papers receiving 3.0k citations

Peers

Countries citing papers authored by Martin Lenter

Since Specialization

Citations

This map shows the geographic impact of Martin Lenter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Lenter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Lenter more than expected).

Fields of papers citing papers by Martin Lenter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Lenter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Lenter. The network helps show where Martin Lenter may publish in the future.

Co-authorship network of co-authors of Martin Lenter

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Lenter. A scholar is included among the top collaborators of Martin Lenter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Lenter. Martin Lenter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells 2024 ·Molecular Therapy — Methods & Clinical Development ·(unknown), Christine Mayer, Johannes Zuber, Martin Lenter, Benjamin Strobel	6
2	Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies 2022 ·Scientific Reports ·Fabian Heinemann, Peter Groß, (unknown), Hu Sheng Qian, Jonathan R. Hill, Anne Höfer, Danny Jonigk, Anna Mae Diehl, Manal F. Abdelmalek, Martin Lenter, Steven S. Pullen, Paolo Guarnieri, Birgit Stierstorfer	24
3	A genome-wide CRISPR/Cas9 screen to identify phagocytosis modulators in monocytic THP-1 cells 2021 ·Scientific Reports ·(unknown), Eva M. Garrido‐Martín, (unknown), (unknown), Martin Lenter, Johannes Zuber, Michael Schuler	14
4	Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants 2020 ·Nature Communications ·Jonas Weinmann, (unknown), (unknown), Warut Tulalamba, Anca Remes, Jihad El Andari, (unknown), (unknown), (unknown), Susanne Hille, Tanja Schönberger, Norbert Frey, Martin Lenter, Thierry VandenDriessche, Oliver J. Müller, Marinee Chuah, Thorsten Lamla, Dirk Grimm	168
5	Targeting blood-brain-barrier transcytosis – perspectives for drug delivery 2016 ·Neuropharmacology ·Imre Mäger, Axel H. Meyer, Jinghuan Li, Martin Lenter, Tobias Hildebrandt, Germán Leparc, Matthew J. A. Wood	76
6	Design, synthesis and evaluation of MCH receptor 1 antagonists—Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition 2015 ·Bioorganic & Medicinal Chemistry Letters ·Gerald J. Roth, Armin Heckel, (unknown), Thorsten Lehmann, Stephan Müller, Thorsten Oost, K Rudolf, Kirsten Arndt, (unknown), Martin Lenter, Ralf Lotz, Marcus Schindler, Leo Thomas, Dirk Stenkamp	8
7	Design, synthesis and evaluation of MCH receptor 1 antagonists—Part III: Discovery of pre-clinical development candidate BI 186908 2015 ·Bioorganic & Medicinal Chemistry Letters ·Thorsten Oost, Armin Heckel, (unknown), Thorsten Lehmann, Stephan Müller, Gerald J. Roth, K Rudolf, Kirsten Arndt, (unknown), Martin Lenter, Ralf Lotz, (unknown), Michael Markert, Leo Thomas, Dirk Stenkamp	6
8	Large scale preparation of human MHC class II+ integrin β1+ Tregs 2010 ·Journal of Immunological Methods ·(unknown), (unknown), Magdalena Lange, Martin Lenter, (unknown), John Wijdenes, Helmut Jonuleit, Christian Becker	2
9	EGFL6 is increasingly expressed in human obesity and promotes proliferation of adipose tissue-derived stromal vascular cells 2010 ·Molecular and Cellular Biochemistry ·(unknown), Wolfgang Rist, Martin Lenter, Bradford S. Hamilton, Heike Neubauer	31
10	miR-155 Inhibition Sensitizes CD4+ Th Cells for TREG Mediated Suppression 2009 ·PLoS ONE ·Heiko Stahl, Tanja Fauti, Nina D. Ullrich, Tobias Bopp, Jan Kubach, Werner Rust, Paul Labhart, (unknown), Christian Becker, Mathias Hafner, Andreas Weith, Martin Lenter, Helmut Jonuleit, Edgar Schmitt, Detlev Mennerich	72
11	MicroRNA and proteome expression profiling in early‐symptomatic α‐synuclein(A30P)‐transgenic mice 2008 ·PROTEOMICS - CLINICAL APPLICATIONS ·Frank Gillardon, Matthias Mack, Wolfgang Rist, Cathrin Schnack, Martin Lenter, Tobias Hildebrandt, Bastian Hengerer	56
12	FPRL‐1 induces modifications of migration‐associated proteins in human neutrophils 2006 ·PROTEOMICS ·Karsten Boldt, Wolfgang Rist, (unknown), Andreas Weith, Martin Lenter	24
13	In Vivo Human MCP-1 Transfection in Porcine Arteries by Intravascular Electroporation 2005 ·Pharmaceutical Research ·Randolph Seidler, (unknown), (unknown), (unknown), (unknown), Dietmar Rabussay, Henri Doods, Martin Lenter	7
14	Stabilized Nonviral Formulations for the Delivery of MCP-1 Gene into Cells of the Vasculoendothelial System 2004 ·Pharmaceutical Research ·Martin Lenter, Patrick Garidel, Jaroslav Pelisek, Ernst Wagner, Manfred Ogris	12
15	Molecular Cloning and Characterization of Endosialin, a C-type Lectin-like Cell Surface Receptor of Tumor Endothelium 2001 ·Journal of Biological Chemistry ·Sven Christian, Horst Ahorn, Andreas Koehler, Frank Eisenhaber, (unknown), Pilar Garin‐Chesa, John E. Park, Wolfgang J. Rettig, Martin Lenter	127
16	Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts 1999 ·Journal of Biological Chemistry ·John E. Park, Martin Lenter, (unknown), Pilar Garin‐Chesa, Lloyd J. Old, Wolfgang J. Rettig	466
17	Mouse fibroblast‐activation protein 1998 ·European Journal of Biochemistry ·(unknown), Barbara Enenkel, John E. Park, Martin Lenter, Wolfgang J. Rettig, (unknown), Andreas Schnapp	59
18	A novel soluble form of mouse VCAM‐1 is generated from a glycolipid‐anchored splicing variant 1994 ·European Journal of Immunology ·Michael Hahne, Martin Lenter, Ute Jäger, Dietmar Vestweber	22
19	Structure of the K24 antigen of E. coli O83:K24:H, a polymer that consists of α-Kdop and glycerol phosphate 1990 ·Carbohydrate Research ·Martin Lenter, Barbara Jann, Klaus Jann	3
20	Structure of the K16 antigen from escherichia coli O7:K16:H-, A Kdo-containing capsular polysaccharide 1990 ·Carbohydrate Research ·Martin Lenter, Barbara Jann, Klaus Jann	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact